← Every company
Ascendis Pharma A/S Patents
What Ascendis Pharma A/S has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
ASND on carbonthat →Filings on file
43
Granted
2
Still pending
41
Filed under
10 names
43 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| DEGRADABLE HYALURONIC ACID HYDROGELSA61K 47/6903, C08L 5/08, A61K 47/61Filed as Ascendis Pharma A/S2026-03-05Sebastian STARK | pending |
| IL-2 ConjugatesA61K 47/542, A61K 47/60, C07K 14/55, A61P 35/02, A61P 35/00, A61K 38/00, A61K 47/183, C07K 1/1077Filed as Ascendis Pharma Oncology Division A/S2026-01-21Dr. Kennett Sprogøe | pending |
| CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTSA61K 47/60, A61K 38/22, A61K 47/62, A61K 47/542, A61K 47/545, A61P 9/02, A61P 19/08, A61K 9/0019Filed as ASCENDIS PHARMA GROWTH DISORDERS A/S2025-12-15Dr. Kennett Sprogøe | pending |
| AUTO INJECTOR WITH RECONSTITUTION HANDLING SUPPORTA61M 5/19, A61M 5/20, A61M 5/2066, A61M 5/2448, A61M 5/24, A61M 5/3146, A61M 5/31511, A61M 5/31568, A61M 5/31578, A61M 5/31583, A61M 5/44, A61M 5/445, A61M 5/484, A61M 5/486, A61M 5/488, A61M2005/2013, A61M2005/2451, A61M2005/31588, A61M2205/215, A61M2205/3306, A61M2205/3317, A61M2205/3327, A61M2205/3331, A61M2205/3368, A61M2205/36, A61M2205/3673, A61M2205/368, A61M2205/50, A61M2205/502, A61M2205/581, A61M2205/583, A61M2205/6054, A61M2205/6063, A61M2205/6072, A61M2205/6081, A61M2205/8206Filed as Ascendis Pharma A/S2025-12-03Steen Jensen | pending |
| Novel Cancer Treatments With IL-2 ConjugatesA61K 47/60, A61P 35/00, A61K 9/0019, A61K 45/06, C07K 14/55Filed as Ascendis Pharma Oncology Division A/S2025-11-04Vibeke MILLER BREINHOLT | pending |
| Incremental Dose Finding in Controlled-Release PTH CompoundsA61K 47/593, A61K 47/60, A61K 38/29, A61K 47/54, A61P 5/18, A61K 9/0019, A61K 47/10, A61K 47/18, A61K 47/22, A61K 47/34Filed as Ascendis Pharma Bone Diseases A/S2025-10-09Dr. David Brian Karpf | pending |
| Method of Treatment of a Thoracolumbar Deformity in a Human Subject with AchondroplasiaA61K 47/60, A61K 38/2242, A61P 21/00, A61P 19/08, A61B 5/4566, A61B 5/4848Filed as Ascendis Pharma Growth Disorders A/S2025-09-17Bent Winding | pending |
| Compounds of Drugs With an Albumin Binding MoietyFiled as Ascendis Pharma A/S2025-09-04Kennett Sprogøe | pending |
| Multi-Albumin Binding CompoundsA61K 47/542, A61K 47/60, A61K 47/61, A61K 47/55, A61K 47/64, A61P 3/10Filed as Ascendis Pharma A/S2025-08-26Kennett SPROGØE | pending |
| Conjugate Comprising an IL-2 MoietyC07K 14/55, A61K 47/542, A61K 47/60, A61P 35/00, A61K 38/00, A61K 38/2013, A61K 39/3955, A61K2300/00, C07K 16/2818, C07K 17/08Filed as ASCENDIS PHARMA ONCOLOGY DIVISION A/S2025-08-22Nina GUNNARSSON | pending |
| Liquid pharmaceutical formulations of PTH ConjugatesA61K 47/60, A61K 9/08, A61K 38/29, A61K 47/545, A61P 5/18, A61K 9/0019, A61K 47/10, A61K 47/12, A61K 47/183, A61K 47/20, A61K 47/26Filed as Ascendis Pharma Bone Diseases A/S2025-07-24Anja R.H. SKANDS | pending |
| Dry Pharmaceutical Formulations of CNP ConjugatesA61K 9/0019, A61K 9/19, A61K 38/22, A61K 38/2242, A61K 47/54, A61K 47/60, A61P 19/00, A61P 19/08, A61K 38/27, A61K 47/12, A61K 47/18, A61K 47/183, A61K 47/22, A61K 47/26Filed as Ascendis Pharma Growth Disorders A/S2025-07-11Anja R.H. SKANDS | pending |
| Drug Compounds Comprising Albumin-Binding MoietiesA61K 47/542, A61K 47/64, A61P 3/10, A61K 9/0019Filed as Ascendis Pharma A/S2025-07-01Kennett SPROGØE | pending |
| DRUG CONJUGATES FOR THE TREATMENT OF OCULAR DISORDERSA61K 47/61, A61K 47/6903, A61K 47/6845, A61K 47/6889, A61K 47/6803, A61P 27/02, C07K 16/22, C07K2317/55Filed as Ascendis Pharma Ophthalmology Division A/S2025-06-30Burkhardt Laufer | pending |
| METHODS OF PRODUCING HYDROGEL MICROSPHERESA61K 47/6927, C08B 37/00, C08B 37/0072, A61K 47/61, A61K 47/6903, A61K 31/738, C08B 37/0003, C08J 3/24Filed as Ascendis Pharma A/S2025-06-30Sebastian Stark | pending |
| METHOD OF IMPROVING SKELETAL MUSCLE FUNCTIONA61K 47/60, A61K 31/506, A61K 9/0019, A61K2300/00Filed as Ascendis Pharma Growth Disorders A/S2025-04-29Bent Winding | pending |
| Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily SomatropinA61K 38/27, A61P 5/06Filed as ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S2025-04-23Dr. Kennett SPROGØE | pending |
| PTH Treatment Regimen Comprising Two PTH CompoundsA61K 47/60, A61P 5/18, A61P 5/20, A61K 9/0019, A61K 38/29, G01N 33/84, G01N2800/52Filed as Ascendis Pharma Bone Diseases A/S2025-04-11Kennett SPROGØE | pending |
| AUTO INJECTOR WITH CHARGER SAFETYA61M 5/20, A61M 5/24, A61M 5/3202, A61M2005/2411, A61M2205/50, A61M2205/502, A61M2205/82, A61M2205/8206, A61M2205/8237, A61M2205/8262Filed as Ascendis Pharma A/S2025-04-09Jan Olesen | pending |
| AUTO INJECTOR WITH TEMPERATURE CONTROLA61M 5/2066, A61M 5/20, A61M 5/24, A61M 5/2448, A61M 5/31511, A61M 5/31573, A61M 5/31576, A61M 5/326, A61M2005/2411, A61M2005/31588, A61M2005/3267, A61M2205/332, A61M2205/3368, A61M2205/50, A61M2205/502, A61M2205/6063, A61M2205/82, A61M2205/8206Filed as Ascendis Pharma A/S2025-04-09Per Mølgaard Pedersen | pending |
| FRONT LOADED AUTO INJECTOR FOR ADMINISTERING A MEDICAMENTA61M 5/2066, A61M 5/20, A61M 5/24, A61M 5/2448, A61M 5/31511, A61M 5/31573, A61M 5/31576, A61M 5/326, A61M2005/2411, A61M2005/31588, A61M2005/3267, A61M2205/332, A61M2205/3368, A61M2205/50, A61M2205/502, A61M2205/6063, A61M2205/82, A61M2205/8206Filed as Ascendis Pharma A/S2025-04-09Paul Erik Fabricius | pending |
| Controlled-Release PTH CompoundA61K 47/60, A61K 38/29, A61K 47/58, A61K 47/61, A61K 47/645, A61K 47/545, A61K 47/54, A61K 47/59, A61P 1/02, A61P 7/00, A61P 7/04, A61P 17/14, A61P 19/02, A61P 5/18, A61P 19/08, A61P 29/00, A61P 19/10, A61K 9/0019, A61K 9/1647, A61K 47/34Filed as ASCENDIS PHARMA BONE DISEASES A/S2025-03-12Kennett Sprogøe | pending |
| AUTO INJECTOR WITH VARIABLE PLUNGER FORCEA61M 5/20, A61M 5/31576, A61M 5/19, A61M 5/2066, A61M 5/315, A61M 5/31501, A61M 5/31511, A61M 5/31535, A61M 5/31566, A61M 5/31596, A61M 5/482, A61M 5/484, A61M 5/488, A61M2005/2006, A61M2005/2013, A61M2005/2026, A61M2005/31508, A61M2005/31516, A61M2005/3152, A61M2005/31588, A61M2205/103, A61M2205/215, A61M2205/332, A61M2205/3327, A61M2205/3331, A61M2205/3365, A61M2205/50, A61M2205/6072, A61M2205/6081, A61M2205/8206Filed as Ascendis Pharma A/S2025-02-12Henrik Egesborg | pending |
| HYDROGEL CROSS-LINKED HYALURONIC ACID PRODRUG COMPOSITIONS AND METHODSA61K 47/61, A61K 47/6903, A61P 27/02, A61K 9/0019, A61K 9/0048, A61K 39/395, A61K2039/505, C07K 16/22, C07K2317/567, C07K2317/76, C07K2317/94Filed as Ascendis Pharma A/S2025-01-23Sebastian Stark | pending |
| AUTO INJECTOR WITH ADAPTABLE AIR-SHOT MECHANISMA61M 5/3146, A61M 5/20, A61M 5/24, A61M 5/31511, A61M2005/2411, A61M2205/215, A61M2205/3368, A61M2205/6018, A61M2205/6054, A61M2205/6063, A61M2205/6072Filed as Ascendis Pharma A/S2025-01-15Per Mølgaard Pedersen | pending |
| PTH ProdrugsA61K 47/56, A61K 47/60, A61K 38/29, A61K 47/545, A61K 47/54, A61P 1/02, A61P 5/20, A61P 7/04, A61P 17/14, A61P 19/02, A61P 5/18, A61P 29/00, A61P 19/10, A61K 9/0019, C07K 14/575Filed as ASCENDIS PHARMA BONE DISEASES A/S2024-12-23Dr. Kennett Sprogøe | pending |
| CNP PRODRUGS WITH LARGE CARRIER MOIETIESA61K 38/2242, A61K 47/60, A61P 19/08, A61K 31/4015, A61K 47/183, A61K 47/20, C07K 14/58Filed as ASCENDIS PHARMA GROWTH DISORDERS A/S2024-12-19Dr. Harald Rau | pending |
| CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITYA61K 47/60, A61K 38/22, A61P 19/00, Y02A 50/30Filed as ASCENDIS PHARMA GROWTH DISORDERS A/S2024-12-06Dr. Kennett SPROGØE | pending |
| Liquid Pharmaceutical Formulations of CNP CompoundsA61K 9/08, A61K 38/2242, A61K 47/12, A61K 47/60, A61K 47/10, A61K 47/26Filed as Ascendis Pharma Growth Disorders A/S2024-11-19Ulrich HERSEL | pending |
| CNP PRODRUGS WITH CARRIER ATTACHMENT AT THE RING MOIETYA61K 47/60, A61P 5/06, A61P 19/08, A61K 38/22Filed as ASCENDIS PHARMA GROWTH DISORDERS A/S2024-10-25Dr. Harald RAU | pending |
| PRODRUG COMPRISING A DRUG-LINKER CONJUGATEA61K 31/553, A61K 47/542, A61K 47/65, A61K 47/545, A61K 47/54, A61K 47/60, A61K 38/1709, A61K 38/18, A61K 38/26Filed as Ascendis Pharma A/S2024-10-18Felix Cleemann | pending |
| Novel Polymeric hGH ProdrugsA61K 47/60, A01G 17/005, A61K 38/27, A61P 43/00, A61P 13/12, A61P 5/06, A01G 2/00, A01G 7/06, A61K 9/0019, A61K 9/08, A61K 9/19, A61K 47/12, A61K 47/20, A61K 47/26, C07K 14/61, C08G 65/3348, C08G2650/06Filed as ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S2024-09-20Dr. Thomas Kurpiers | pending |
| CNP PRODRUGSA61K 47/60, A61K 38/22, A61K 38/2242, A61P 27/02, A61P 1/02, A61P 5/10, A61P 19/00, A61P 43/00, A61P 17/00, A61P 19/02, A61P 19/08, A61P 25/00, A61K 9/0019, A61K 38/1709Filed as ASCENDIS PHARMA GROWTH DISORDERS A/S2024-08-23Dr. Kennett Sprogøe | pending |
| CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITYA61K 47/542, A61K 47/60, A61P 43/00, A61P 19/02, Y02A 50/30, A61K 38/22, A61K 38/2242, C07K 14/58Filed as ASCENDIS PHARMA GROWTH DISORDERS A/S2024-08-07Dr. Kennett SPROGØE | pending |
| Novel Cancer Treatments with TLR7/8 AgonistsA61K 47/6903, A61K 47/60, A61P 35/00, A61J 1/14, A61K 39/3955Filed as Ascendis Pharma Oncology Division A/S2024-06-04Vibeke MILLER BREINHOLT | pending |
| Long-Acting Growth Hormone TreatmentA61K 38/27, A61K 47/60, A61P 5/02, A61K 9/0019, A61K 9/19, A61M 5/19Filed as Ascendis Pharma Endocrinology Division A/S2024-05-24Dr. Kennett Sprogøe | pending |
| Effective Doses of CNP ConjugatesA61K 47/60, A61K 38/2242, A61K 47/64, A61P 5/00, A61P 19/08, A61K 9/0019, A61K 38/22Filed as Ascendis Pharma Growth Disorders A/S2024-05-07Kennett Sprogøe | pending |
| AUTO INJECTOR WITH DETECTION OF USED CARTRIDGE AND ASSOCIATED METHODA61M 5/20, A61M 5/3158, A61M 5/2422, A61M 5/31511, A61M2005/2086, A61M2005/2418, A61M2005/31588, A61M2205/276, A61M2205/3317, A61M2205/332, A61M2205/3327, A61M2205/3331, A61M2205/3365, A61M2205/3368, A61M2205/50, A61M2205/502, A61M2205/60, A61M2205/6063, A61M2205/82, A61M2205/8206Filed as Ascendis Pharma A/S2024-05-01Per Mølgaard Pedersen | pending |
| Long-acting PTH compound treatmentsA61K 38/29, A61K 47/60, A61P 19/08, A61K 31/593, A61K 33/06Filed as Ascendis Pharma Bone Diseases A/S2024-03-19Kennett Sprogøe | pending |
| AUTO INJECTOR WITH MEASUREMENT OF BATTERY CAPACITY LEFT BEFORE RE-CHARGING IS REQUIREDA61M 5/20, A61M 5/2422, G01R 31/3835, A61M 5/31576, A61M 5/44, A61M2005/2006, A61M2005/31588, A61M2205/3368, A61M2205/50, A61M2205/583, A61M2205/587, A61M2205/6018, A61M2205/8206Filed as Ascendis Pharma A/S2024-02-16Henrik Egesborg | pending |
| Controlled-Release PTH CompoundA61K 47/60, A61K 38/29, A61K 47/58, A61K 47/61, A61K 47/645, A61K 47/545, A61K 47/54, A61K 47/59, A61P 1/02, A61P 7/00, A61P 7/04, A61P 17/14, A61P 19/02, A61P 5/18, A61P 19/08, A61P 29/00, A61P 19/10, A61K 9/0019, A61K 9/1647, A61K 47/34Filed as ASCENDIS PHARMA BONE DISEASES A/S2024-01-24Kennett Sprogøe | 12295989 |
| AUTO INJECTOR WITH ADAPTABLE AIR-SHOT MECHANISMA61M 5/3146, A61M 5/20, A61M 5/24, A61M 5/31511, A61M2005/2411, A61M2205/215, A61M2205/3368, A61M2205/6018, A61M2205/6054, A61M2205/6063, A61M2205/6072Filed as Ascendis Pharma A/S2024-01-17Per Mølgaard Pedersen | 12226616 |
| CNP PRODRUGS WITH LARGE CARRIER MOIETIESA61K 38/2242, A61K 47/60, A61P 19/08, A61K 31/4015, A61K 47/183, A61K 47/20, C07K 14/58Filed as ASCENDIS PHARMA GROWTH DISORDERS A/S2024-01-08Dr. Harald Rau | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on ASND
Company overviewEverything on ASND in one place, with the price.SEC filingsWhat ASND's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat ASND's own officers and directors buy and sell.LobbyingWhat ASND spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on ASND's account, and who they worked for.Federal contractsWhat federal agencies pay ASND.